How much revenue does Wockhardt make?

Wockhardt reported 30.12 billion INR in revenue for fiscal year 2025, up 7.6% from 27.98 billion INR in fiscal year 2024. In Q1 2026 revenue was 7.38 billion INR.

Where does Wockhardt make most of its revenue?

Europe: 51% of revenue by region in fiscal year 2025, followed by Rest of the World (24%).

What companies are similar to Wockhardt?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ajanta Pharma Limited (AJANTPHARM.NS), J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS), Emcure Pharmaceuticals L (EMCURE.NS), Granules India Limited (GRANULES.NS).

Wockhardt Limited (WOCKPHARMA.NS) Stock

About Wockhardt Limited

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer ...

At a glance

Wockhardt reported revenue of 30.12 billion INR for fiscal year 2025, up 7.6% from fiscal year 2024, and net income of -470.00 million INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 7.38 billion INR, down 0.1% from a year before. Europe was its largest region in fiscal year 2025, with 51% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.